Derma Sciences Inc. (DSCI) Cut to Hold at Zacks Investment Research
According to Zacks, “Derma Sciences, Inc. is engaged in the development, marketing and sales of proprietary and non-proprietary topical, nutrient-based wound care products for the management of certain chronic, non-healing skin ulcerations such as pressure and venous ulcers, surgical incisions and burns. (PRESS RELEASE) “
Separately, TheStreet raised shares of Derma Sciences from a sell rating to a hold rating in a report on Tuesday, August 9th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $7.35.
Derma Sciences (NASDAQ:DSCI) opened at 4.70 on Tuesday. The firm has a 50-day moving average of $4.68 and a 200-day moving average of $4.21. Derma Sciences has a 1-year low of $2.85 and a 1-year high of $5.99. The stock’s market capitalization is $133.03 million.
Derma Sciences (NASDAQ:DSCI) last posted its quarterly earnings results on Tuesday, August 9th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.16. The firm earned $22.20 million during the quarter, compared to analysts’ expectations of $22.40 million. Derma Sciences had a negative net margin of 21.19% and a negative return on equity of 11.74%. Equities research analysts anticipate that Derma Sciences will post ($0.04) EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC raised its position in shares of Derma Sciences by 23.3% in the first quarter. Renaissance Technologies LLC now owns 541,800 shares of the company’s stock valued at $1,680,000 after buying an additional 102,500 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in shares of Derma Sciences by 170.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 117,271 shares of the company’s stock valued at $364,000 after buying an additional 73,911 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Derma Sciences by 2.5% in the first quarter. Franklin Resources Inc. now owns 2,684,500 shares of the company’s stock valued at $8,322,000 after buying an additional 65,192 shares during the last quarter. Emerald Acquisition Ltd. bought a new position in shares of Derma Sciences during the second quarter valued at $202,000. Finally, Granahan Investment Management Inc. MA raised its position in shares of Derma Sciences by 5.1% in the first quarter. Granahan Investment Management Inc. MA now owns 1,028,460 shares of the company’s stock valued at $3,188,000 after buying an additional 50,142 shares during the last quarter. Institutional investors own 62.44% of the company’s stock.
About Derma Sciences
Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Derma Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.